(Q43194570)

15 November 2017

title

Treatment of type I gastric neuroendocrine tumors with somatostatin analogs (English)

1 reference

15 November 2017

author name string

Mehnaaz Sultan Khuroo

series ordinal

1

1 reference

15 November 2017

Mohammad Sultan Khuroo

series ordinal

2

1 reference

15 November 2017

Naira Sultan Khuroo

series ordinal

3

1 reference

15 November 2017

publication date

14 January 2010

1 reference

Journal of Gastroenterology and Hepatology

15 November 2017

published in

1 reference

15 November 2017

volume

25

1 reference

15 November 2017

issue

3

1 reference

15 November 2017

page(s)

548-554

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06131.X

15 November 2017

1 reference

An analysis of 8305 cases of carcinoid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06131.X

The multiple endocrine neoplasia type I gene locus is involved in the pathogenesis of type II gastric carcinoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06131.X

Long-acting somatostatin analogues are an effective treatment for type 1 gastric carcinoid tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06131.X

One-year follow-up study of patients with enterochromaffin-like cell carcinoids after treatment with octreotide long-acting release

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06131.X

Gastric endocrine tumors type I: treatment with long-acting somatostatin analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06131.X

Type 1 and 2 gastric carcinoid tumors: long-term follow-up of the efficacy of treatment with a slow-release somatostatin analogue

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06131.X

Presentation, treatment, and outcome of type 1 gastric carcinoid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06131.X

Gastrin is the most important factor in ECL tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06131.X

Treatment of ECL cell carcinoids with octreotide LAR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06131.X

Rationale for the use of somatostatin analogs as antitumor agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06131.X

Gastroscopic follow up of pernicious anaemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06131.X

Treatment of type II gastric carcinoid tumors with somatostatin analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06131.X

10.1111/J.1440-1746.2009.06131.X

21 January 2018

Identifiers

DOI

1 reference

15 November 2017

1 reference